-- Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial
evaluating rezatapopt as monotherapy in platinum-resistant/refractory
ovarian cancer patients with a TP53 Y220C mutation
-- Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug
Administration for the treatment of TP53 Y220C positive ovarian cancer
-- New England Journal of Medicine published first-in-human rezatapopt data
showing selective reactivation of mutant p53 in advanced solid tumors
-- Rezatapopt New Drug Application submission for
platinum-resistant/refractory ovarian cancer planned in first quarter of
2027
-- Cash, cash equivalents, and marketable securities of $112.9 million as of
December 31, 2025 providing expected cash runway to end of second quarter
of 2027
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the full year ended December 31, 2025, and provided a corporate update.
"2025 was an important and productive year for PMV Pharma as we reported positive Phase 2 interim data from the registrational PYNNACLE clinical trial and made significant progress in enrolling the study," said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma. "We look forward to submitting an NDA in the first quarter of 2027 for rezatapopt in platinum-resistant/refractory ovarian cancer."
PYNNACLE Phase 2 Monotherapy Update:
-- Enrollment is on track in the Phase 2 monotherapy portion of the PYNNACLE
clinical trial. The multicenter, single-arm, registrational Phase 2 study
is assessing rezatapopt as monotherapy at a dose of 2000 mg once-daily in
patients with TP53 Y220C advanced solid tumors.
-- PMV Pharma anticipates submitting a New Drug Application (NDA) for
rezatapopt in platinum-resistant/refractory ovarian cancer patients with
a TP53 Y220C mutation in the first quarter of 2027.
Full Year 2025 and Recent Corporate Highlights:
-- On March 2, 2026, the U.S. Food and Drug Administration (FDA) granted
Orphan Drug Designation $(ODD)$ to rezatapopt for the treatment of TP53
Y220C positive ovarian cancer, fallopian tube cancer, and primary
peritoneal cancer. The FDA provides ODD status to drugs intended for the
safe and effective treatment, diagnosis, or prevention of rare diseases
that affect fewer than 200,000 people in the U.S. Benefits of the
designation may include exemption from certain FDA fees, financial
incentives for qualified clinical development, and seven years of market
exclusivity in the U.S. if the treatment is approved.
-- Phase 1 results from the ongoing Phase 1/2 PYNNACLE study were published
in the New England Journal of Medicine, "Phase 1 Study of Rezatapopt, a
p53 Reactivator, in TP53 Y220C-Mutated Tumors." The manuscript
highlighted that rezatapopt demonstrated antitumor activity in heavily
pretreated patients across multiple solid tumor types which provided
proof-of-concept for p53 reactivation. Clinical activity and biomarker
data were consistent with selective binding to the Y220C pocket and
restoration of wild-type p53 tumor suppressor function.
-- Updated data from the ongoing PYNNACLE Phase 2 trial were presented as an
oral presentation at the 2025 AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics based on a September 4, 2025
data cut-off.
-- 34% overall response rate $(ORR)$ observed among 103 evaluable
patients across all cohorts with a median duration of response of
7.6 months.
-- 46% ORR observed among 48 evaluable patients in ovarian cancer
cohort with a median duration of response of 8.0 months.
-- Treatment-related adverse events (TRAEs) were mostly Grade 1-2
with the most frequent TRAEs observed (>15%) being nausea, fatigue,
blood creatinine increased, and alanine aminotransferase $(ALT)$
increased.
-- Natural history study results were also presented at the 2025
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Therapeutics where TP53 Y220C--mutant advanced solid tumors were
associated with poor outcomes reinforcing the significant unmet medical
need addressed by rezatapopt.
-- New findings from the rezatapopt PYNNACLE Phase 2 trial in ovarian cancer
were presented at the 2026 European Society of Gynecologic Oncology
Congress, demonstrating robust and consistent ORRs across key ovarian
cancer subgroups.
-- The ORR subgroup data included those with platinum-resistant,
platinum-refractory disease, prior systemic therapies and folate
receptor alpha status, that provide further evidence of the broad
efficacy of rezatapopt within ovarian cancer patients.
-- After the September 4, 2025 data cut-off, among the 48 evaluable
patients in the ovarian cancer cohort, a 50% ORR was observed with
23 confirmed responses and one unconfirmed partial response.
Fiscal Year 2025 Financial Results
-- As of December 31, 2025, PMV Pharma had $112.9 million in cash, cash
equivalents, and marketable securities, compared to $183.3 million at
December 31, 2024. Net cash used in operations was $73.6 million for the
year ended December 31, 2025, compared to $51.3 million for the year
ended December 31, 2024.
-- Net loss for the year ended December 31, 2025, was $77.7 million compared
to $58.7 million for the year ended December 31, 2024.
-- Research and development (R&D) expenses were $69.9 million for the year
ended December 31, 2025, compared to $58.5 million for the year ended
December 31, 2024. The increase in R&D expenses was primarily related to
clinical expenses for advancing rezatapopt, the Company's lead product
candidate.
-- General and administrative (G&A) expenses were $16.3 million for the year
ended December 31, 2025, compared to $26.9 million for the year ended
December 31, 2024. The decrease in G&A expenses was primarily due to
lower facility-related and personnel costs following the relocation of
the Company's lab and office space and staff reductions in the prior
year.
About Rezatapopt
Rezatapopt (PC14586) is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring the wild-type tumor-suppressor function. The U.S. Food and Drug Administration granted Fast Track designation to rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug Designation for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
About the PYNNACLE Clinical Trial
The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. The primary objective of the Phase 1 portion of the clinical trial was to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D) of rezatapopt when administered orally to patients. Safety, tolerability, pharmacokinetics and effects on biomarkers were also assessed. The Phase 2 portion is a registrational, single arm, expansion basket clinical trial comprising five cohorts (ovarian, lung, breast, and endometrial cancers, and other solid tumors) with the primary objective of evaluating the efficacy of rezatapopt at the RP2D in patients with TP53 Y220C and KRAS wild-type advanced solid tumors, conducted across approximately 70 sites.
For more information about the Phase 1/2 PYNNACLE clinical trial, refer to www.clinicaltrials.gov (NCT trial identifier NCT04585750).
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's future plans or expectations for rezatapopt, including our ability to obtain approval as a treatment option as a monotherapy, expectations regarding timing, enrollment status and success of the Phase 2 portion of the current clinical trial for rezatapopt and filing of an New Drug Application (NDA) for platinum-resistant/refractory ovarian cancer, the benefits of FDA's grant of Orphan Drug Designation (ODD) for rezatapopt, and the timing and expectations with respect to our projected cash runway. Any forward-looking statements in this statement are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in
(MORE TO FOLLOW) Dow Jones Newswires
March 06, 2026 08:00 ET (13:00 GMT)
Comments